发明名称 OLIGONUCLEOTIDES COMPRISING A C5-MODIFIED PYRIMIDINE
摘要 One aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one ligand. In certain embodiments, a ligand is bound to only one of the two oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, both of the oligonucleotide strands of the double-stranded oligonucleotide independently comprise a bound ligand. In certain embodiments, the oligonucleotide strands comprise at least one modified sugar moiety. In certain embodiments, a phosphate linkage in one or both of the strands of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5.beta.-cholanic acid. Another aspect of the present invention relates to a single-stranded oligonucleotide comprising at least one ligand. In certain embodiments, the oligonucleotide comprises at least one modified sugar moiety. In certain embodiments, a phosphate linkage of the oligonucleotide has been replaced with a phosphorothioate or phosphorodithioate linkage. In a preferred embodiment, the ligand is cholesterol or 5.beta.-cholanic acid. The ligand improves the pharmacokinetic properties of the oligonucleotide.
申请公布号 CA2562151(C) 申请公布日期 2016.09.06
申请号 CA20052562151 申请日期 2005.04.29
申请人 ALNYLAM PHARMACEUTICALS, INC. 发明人 MANOHARAN, MUTHIAH;RAJEEV, KALLANTHOTTATHIL G.
分类号 C07H21/00;A61K31/7052;A61K31/7064;A61K31/7076;A61K48/00;A61P25/28;A61P29/00;A61P31/00;A61P33/00;A61P35/00;C07H21/02;C12N15/11;C12N15/113 主分类号 C07H21/00
代理机构 代理人
主权项
地址